<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SILENOR- doxepin hydrochloride tablet </strong><br>Pernix Therapeutics, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Silenor safely and effectively. See full prescribing information for Silenor.<br> <br>Silenor<span class="Sup">®</span> (doxepin) tablets for oral administration<br>Initial U.S. Approval: 1969</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Silenor (doxepin) tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulties with sleep maintenance. (<a href="#S1">1</a>, <a href="#S14">14</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> Initial dose:  6 mg, once daily for adults (<a href="#S2.1">2.1</a>) and 3 mg, once daily for the elderly. (<a href="#S2.1">2.1</a>, <a href="#S2.2">2.2</a>)</li>
<li> Take within 30 minutes of bedtime. Total daily dose should not exceed 6 mg. (<a href="#S2.3">2.3</a>)</li>
<li> Should not be taken within  3 hours of  a meal. (<a href="#S2.3">2.3</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>3 mg and 6 mg tablets. Tablets <span class="Underline">not</span> scored. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to doxepin hydrochloride, inactive ingredients, or other dibenzoxepines. (<a href="#S4.1">4.1</a>)</li>
<li> Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (<a href="#S4.2">4.2</a>)</li>
<li> Untreated narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or severe <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. (<a href="#S4.3">4.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> Need to Evaluate for Co-morbid Diagnoses: Reevaluate if <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> persists after 7 to 10 days of use. (<a href="#S5.1">5.1</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span>, behavioral changes, complex behaviors:  May include "Sleep-driving" and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Immediately evaluate any new onset behavioral changes. (<a href="#S5.2">5.2</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>: Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidal thinking may occur. Prescribe the least amount feasible to avoid <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span>. (<a href="#S5.3">5.3</a>)</li>
<li> CNS-depressant effects: Use can impair alertness and motor coordination. Avoid engaging in hazardous activities such as operating a motor vehicle or heavy machinery after taking drug. (<a href="#S5.4">5.4</a>) Do not use with alcohol. (<a href="#S5.4">5.4</a>, <a href="#S7.3">7.3</a>)</li>
<li> Potential additive effects when used in combination with CNS depressants or sedating antihistamines. Dose reduction may be needed. (<a href="#S5.4">5.4</a>, <a href="#S7.4">7.4</a>)</li>
<li> Patients with severe <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>: Silenor is ordinarily not recommended for use in this population. (<a href="#S8.7">8.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>The most common treatment-emergent adverse reactions, reported in ≥ 2% of patients treated with Silenor, and more commonly than in patients treated with placebo, were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>/sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>. (<a href="#S6.1">6.1</a>)</li></ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pernix Therapeutics, LLC. at 1-877-SILENOR (745-3667) and www.silenor.com or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li> MAO inhibitors: Silenor should not be administered in patients on MAOIs within the past two weeks. (<a href="#S4.2">4.2</a>)</li>
<li> Cimetidine: Increases exposure to doxepin. (<a href="#S7.2">7.2</a>)</li>
<li> Alcohol:  Sedative effects may be increased with doxepin. (<a href="#S7.3">7.3</a>, <a href="#S5.4">5.4</a>)</li>
<li> CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin. (<a href="#S7.4">7.4</a>, <a href="#S5.4">5.4</a>)</li>
<li> Tolazamide: A case of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> has been reported. (<a href="#S7.5">7.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li> Pregnancy: Based on animal data, may cause fetal harm. (<a href="#S8.1">8.1</a>)</li>
<li> Nursing Mothers: Infant exposure via human milk. (<a href="#S8.3">8.3</a>)</li>
<li> Pediatric Use: Safety and effectiveness have not been evaluated. (<a href="#S8.4">8.4</a>)</li>
<li> Geriatric Use: The recommended starting dose is 3 mg. Monitor prior to considering dose escalation. (<a href="#S2.2">2.2</a>, <a href="#S8.5">8.5</a>)</li>
<li> Use in Patients with Comorbid Illness: Initiate treatment with 3 mg in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or tendency to <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. (<a href="#S8.6">8.6</a>,  <a href="#S4.3">4.3</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div><div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1.	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2.	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1.	Dosing in Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2.	Dosing in the Elderly</a></h2>
<h2><a href="#section-2.3" class="toc">2.3.	Administration</a></h2>
<h1><a href="#section-3" class="toc">3.	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4.	CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1.	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2.	Co-administration with Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
<h2><a href="#section-4.3" class="toc">4.3.	<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></a></h2>
<h1><a href="#section-5" class="toc">5.	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1.	Need to Evaluate for Comorbid Diagnoses</a></h2>
<h2><a href="#section-5.2" class="toc">5.2.	<span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal Thinking</span> and Behavioral Changes</a></h2>
<h2><a href="#section-5.3" class="toc">5.3.	<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk and Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4.	CNS Depressant Effects</a></h2>
<h1><a href="#section-6" class="toc">6.	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1.	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2.	Studies Pertinent to Safety Concerns for Sleep-promoting Drugs</a></h2>
<h2><a href="#section-6.3" class="toc">6.3.	Other Reactions Observed During the Pre-marketing Evaluation of Silenor</a></h2>
<h1><a href="#section-7" class="toc">7.	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1.	Cytochrome P450 Isozymes</a></h2>
<h2><a href="#section-7.2" class="toc">7.2.	Cimetidine </a></h2>
<h2><a href="#section-7.3" class="toc">7.3.	Alcohol</a></h2>
<h2><a href="#section-7.4" class="toc">7.4.	CNS Depressants and Sedating Antihistamines</a></h2>
<h2><a href="#section-7.5" class="toc">7.5.	Tolazamide</a></h2>
<h1><a href="#section-8" class="toc">8.	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1.	Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.2.	Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3.	Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4.	Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5.	Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6.	Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7.	Use in Patients with <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">Sleep Apnea</span></a></h2>
<h1><a href="#section-9" class="toc">9.	DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1.	Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2.	Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3.	<span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10.	OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1.	Signs and Symptoms of Excessive Doses</a></h2>
<h2><a href="#section-10.2" class="toc">10.2.	Signs and Symptoms of Critical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h2><a href="#section-10.3" class="toc">10.3.	Recommended Management</a></h2>
<h1><a href="#section-11" class="toc">11.	DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12.	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1.	Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2.	Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3.	Pharmacokinetics</a></h2>
<h2><a href="#section-12.4" class="toc">12.4.	 Drug Interactions</a></h2>
<h2><a href="#section-12.5" class="toc">12.5.	 Special Populations</a></h2>
<h1><a href="#section-13" class="toc">13.	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1.	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14.	CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1.	Controlled Clinical Trials</a></h2>
<h1><a href="#section-15" class="toc">16.	HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h2><a href="#section-15.1" class="toc">16.1.	How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2.	Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17.	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1.	Sleep-driving and Other Complex Behaviors </a></h2>
<h2><a href="#section-16.2" class="toc">17.2.	<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> risk and Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>:</a></h2>
<h2><a href="#section-16.3" class="toc">17.3.	Administration Instructions </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1.	INDICATIONS AND USAGE</h1>
<p class="First">Silenor is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration [<span class="Italics">see <a href="#S14">Clinical Studies (14)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2.	DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose of Silenor should be individualized.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1.	Dosing in Adults</h2>
<p class="First">The recommended dose of Silenor for adults is 6 mg once daily. A 3 mg once daily dose may be appropriate for some patients, if clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2.	Dosing in the Elderly</h2>
<p class="First">The recommended starting dose of Silenor in elderly patients (≥ 65 years old) is 3 mg once daily. The daily dose can be increased to 6 mg, if clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3.	Administration</h2>
<p class="First">Silenor should be taken within 30 minutes of bedtime.</p>
<p>To minimize the potential for next day effects, Silenor should not be taken within 3 hours of a meal [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]<span class="Italics">.</span></p>
<p>The total Silenor dose should not exceed 6 mg per day.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3.	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Silenor is an immediate-release, oval-shaped, tablet for oral administration available in strengths of 3 mg and 6 mg. The tablets are blue (3 mg) or green (6 mg) and are debossed with 3 or 6, respectively, on one side and SP on the other. Silenor tablets are <span class="Underline">not</span> scored.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4.	CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1.	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Silenor is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to doxepin HCl, any of its inactive ingredients, or other dibenzoxepines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2.	Co-administration with Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class="First">Serious side effects and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported following the concomitant use of certain drugs with MAO inhibitors. Do not administer Silenor if patient is currently on MAOIs or has used MAOIs within the past two weeks. The exact length of time may vary depending on the particular MAOI dosage and duration of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3.	<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></h2>
<p class="First">Silenor is contraindicated in individuals with untreated narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or severe <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5.	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1.	Need to Evaluate for Comorbid Diagnoses</h2>
<p class="First">Because <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> should be initiated only after careful evaluation of the patient. <span class="Bold">The failure of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. </span>Exacerbation of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or the emergence of new cognitive or behavioral abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with hypnotic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2.	<span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal Thinking</span> and Behavioral Changes</h2>
<p class="First">Complex behaviors such as "sleep-driving" (i.e., driving while not fully awake after ingestion of a hypnotic, with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> for the event) have been reported with hypnotics. These events can occur in hypnotic-naive as well as in hypnotic-experienced persons. Although behaviors such as "sleep-driving" may occur with hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with hypnotics appears to increase the risk of such behaviors, as does the use of hypnotics at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of Silenor should be strongly considered for patients who report a "sleep-driving" episode. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a hypnotic. As with "sleep-driving", patients usually do not remember these events. <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and other neuro-<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> may occur unpredictably.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3.	<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk and Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">In primarily depressed patients, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, including suicidal thoughts and actions (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>), has been reported in association with the use of hypnotics.</p>
<p>Doxepin, the active ingredient in Silenor, is an antidepressant at doses 10- to 100-fold higher than in Silenor. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Risk from the lower dose of doxepin in Silenor can not be excluded.</p>
<p>It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4.	CNS Depressant Effects</h2>
<p class="First">After taking Silenor, patients should confine their activities to those necessary to prepare for bed. Patients should avoid engaging in hazardous activities, such as operating a motor vehicle or heavy machinery, at night after taking Silenor, and should be cautioned about potential impairment in the performance of such activities that may occur the day following ingestion.</p>
<p>When taken with Silenor, the sedative effects of alcoholic beverages, sedating antihistamines, and other CNS depressants may be potentiated [s<span class="Italics">ee <a href="#S5.2">Warnings and Precautions (5.2)</a> and <a href="#S7.3">Drug Interactions (7.3</a>, <a href="#S7.4">7.4)</a></span>]. Patients should not consume alcohol with Silenor [s<span class="Italics">ee <a href="#S5.2">Warnings and Precautions (5.2)</a> and <a href="#S7.3">Drug Interactions (7.3)</a></span>]. Patients should be cautioned about potential additive effects of Silenor used in combination with CNS depressants or sedating antihistamines [s<span class="Italics">ee <a href="#S5.2">Warnings and Precautions (5.2)</a> and <a href="#S7.4">Drug Interactions (7.4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6.	ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Abnormal thinking</span> and behavioral changes <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> risk and worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]. </span>
</li>
<li>CNS Depressant effects <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]. </span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1.	Clinical Trials Experience</h2>
<p class="First">The pre-marketing development program for Silenor included doxepin HCl exposures in 1017 subjects (580 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> patients and 437 healthy subjects) from 12 studies conducted in the United States. 863 of these subjects (580 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> patients and 283 healthy subjects) participated in six randomized, placebo-controlled efficacy studies with Silenor doses of 1 mg, 3 mg, and 6 mg for up to 3-months in duration.</p>
<p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. However, data from the Silenor studies provide the physician with a basis for estimating the relative contributions of drug and non-drug factors to adverse reaction incidence rates in the populations studied.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics">Associated with Discontinuation of Treatment</span></p>
<p>The percentage of subjects discontinuing Phase 1, 2, and 3 trials for an adverse reaction was 0.6% in the placebo group compared to 0.4%, 1.0%, and 0.7% in the Silenor 1 mg, 3 mg, and 6 mg groups, respectively. No reaction that resulted in discontinuation occurred at a rate greater than 0.5%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Adverse Reactions Observed at an Incidence of ≥ 2% in Controlled Trials</span></p>
<p>Table 1 shows the incidence of treatment-emergent adverse reactions from three long-term (28 to 85 days) placebo-controlled studies of Silenor in adult (N=221) and elderly (N=494) subjects with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span>.</p>
<p>Reactions reported by Investigators were classified using a modified MedDRA dictionary of preferred terms for purposes of establishing incidence. The table includes only reactions that occurred in 2% or more of subjects who received Silenor 3 mg or 6 mg in which the incidence in subjects treated with Silenor was greater than the incidence in placebo-treated subjects.</p>
<a name="table1"></a><table width="80%">
<caption><span>Table 1 Incidence (%) of Treatment-Emergent Adverse Reactions in Long-term Placebo-Controlled Clinical Trials</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" valign="bottom">System Organ Class<br>Preferred Term<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center" valign="bottom">Placebo<br>(N=278)</th>
<th class="Rrule" align="center" valign="bottom">Silenor<br>3 mg<br>(N=157)</th>
<th class="Rrule" align="center" valign="bottom">Silenor<br>6 mg<br>(N=203)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes reactions that occurred at a rate of ≥ 2% in any Silenor-treated group and at a higher rate than placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Rrule" align="center" colspan="3"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/Sedation</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td class="Rrule" align="center" colspan="3"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span>/<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td class="Rrule" align="center" colspan="3"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></td>
<td class="Rrule" align="center" colspan="3"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">&lt; 1</td>
</tr>
</tbody>
</table>
<p>The most common treatment-emergent adverse reaction in the placebo and each of the Silenor dose groups was <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>/sedation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2.	Studies Pertinent to Safety Concerns for Sleep-promoting Drugs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics">Residual Pharmacological Effect in <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> Trials</span></p>
<p>Five randomized, placebo-controlled studies in adults and the elderly assessed next-day psychomotor function within 1 hour of awakening utilizing the digit-symbol substitution test (DSST), symbol copying test (SCT), and visual analog scale (VAS) for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, following night time administration of Silenor. </p>
<p>In a one-night, double-blind study conducted in 565 healthy adult subjects experiencing <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span>, Silenor 6 mg showed modest negative changes in SCT and VAS.</p>
<p>In a 35-day, double-blind, placebo-controlled, parallel group study of Silenor 3 and 6 mg in 221 adults with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span>, small decreases in the DSST and SCT occurred in the 6 mg group.</p>
<p>In a 3-month, double-blind, placebo-controlled, parallel group study in 240 elderly subjects with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span>, Silenor 1 mg and 3 mg was comparable to placebo on DSST, SCT, and VAS.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3.	Other Reactions Observed During the Pre-marketing Evaluation of Silenor</h2>
<p class="First">Silenor was administered to 1017 subjects in clinical trials in the United States. Treatment-emergent adverse reactions recorded by clinical investigators were standardized using a modified MedDRA dictionary of preferred terms. The following is a list of MedDRA terms that reflect treatment-emergent adverse reactions reported by subjects treated with Silenor.</p>
<p>Adverse reactions are further categorized by body system and listed in order of decreasing frequency according to the following definitions: <span class="Bold">Frequent</span> adverse reactions are those that occurred on one or more occasions in at least 1/100 subjects; <span class="Bold">Infrequent</span> adverse reactions are those that occurred in fewer than 1/100 subjects and more than 1/1000 subjects. <span class="Bold">Rare</span> adverse reactions are those that occurred in fewer than 1/1000 subjects. Adverse reactions that are listed in Table 1 are not included in the following listing of frequent, infrequent, and rare AEs.</p>
<p><span class="Italics">Blood and Lymphatic System Disorders: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; Rare: <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: </span>Rare: <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>.</p>
<p><span class="Italics">Ear and Labyrinth Disorders: </span>Rare: <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hypoacusis</span>, <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">motion sickness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="375292" conceptname="Perforation of tympanic membrane">tympanic membrane perforation</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>; Rare: <span class="product-label-link" type="condition" conceptid="435802" conceptname="Blepharospasm">blepharospasm</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> decreased.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; Rare: <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="134386" conceptname="Gingival recession">gingival recession</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">haematochezia</span>, lip <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.</p>
<p><span class="Italics">General Disorders and Administration Site Conditions</span>: Infrequent: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; Rare: <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait abnormal</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>.</p>
<p><span class="Italics">Hepatobiliary Disorders: </span>Rare: <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span>Rare: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: Infrequent: <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4322737" conceptname="Infection of tooth">tooth infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>; Rare: <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> staphylococcal, <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span>, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="201218" conceptname="Epidemic vomiting syndrome">gastroenteritis viral</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, infective <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="134520" conceptname="Crushing injury of back">back injury</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>, <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">joint sprain</span>; Rare: bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, <span class="product-label-link" type="condition" conceptid="4148390" conceptname="Laceration">skin laceration</span>.</p>
<p><span class="Italics">Investigations: </span>Infrequent: blood glucose increased; Rare: <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, electrocardiogram ST-T segment abnormal, electrocardiogram <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> abnormal, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">heart rate decreased</span>, neutrophil count decreased, QRS axis abnormal, transaminases increased.</p>
<p><span class="Italics">Metabolism and Nutrition Disorders: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>; Rare: <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span><span class="Italics">: </span>Infrequent: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>; Rare: joint range of motion decreased, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramp</span>, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">sensation of heaviness</span>.</p>
<p><span class="Italics">Neoplasms Benign, Malignant and Unspecified (Including <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">Polyps</span>)</span>: Rare: lung adenocarcinoma stage I, malignant melanoma.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: Frequent: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; Infrequent: <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, parasthesia, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>; Rare: <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">ageusia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="435238" conceptname="Sleep paralysis">sleep paralysis</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope vasovagal</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p><span class="Italics">Psychiatric Disorders</span>: Infrequent: <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="436677" conceptname="Adjustment disorder">adjustment disorder</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; Rare: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4304866" conceptname="Elevated mood">elevated mood</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span>.</p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span>: Rare: <span class="product-label-link" type="condition" conceptid="78473" conceptname="Solitary cyst of breast">breast cyst</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>.</p>
<p><span class="Italics">Renal and Urinary Disorders</span>: Rare: <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>, <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>.</p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>: Infrequent: <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>; Rare: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">crackles lung</span>, <span class="product-label-link" type="condition" conceptid="31057" conceptname="Disorder of pharynx">nasopharyngeal disorder</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span>: Infrequent: <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>; Rare: <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>.</p>
<p><span class="Italics">Surgical and Medical Procedures</span>: Rare: arthrodesis.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span>: Infrequent: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>; Rare: blood pressure inadequately controlled, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>.</p>
<p>In addition, the reactions below have been reported for other tricyclics and may be idiosyncratic (not related to dose).</p>
<p><span class="Italics">Allergic:</span>  photosensitization, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</p>
<p><span class="Italics">Hematologic:</span>  <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7.	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1.	Cytochrome P450 Isozymes</h2>
<p class="First">Silenor is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Silenor is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of Silenor to induce CYP isozymes is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2.	Cimetidine </h2>
<p class="First">Silenor exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly when cimetidine is co-administered with Silenor <span class="Italics">[see <a href="#S12.4">Clinical Pharmacology (12.4)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3.	Alcohol</h2>
<p class="First">When taken with Silenor, the sedative effects of alcohol may be potentiated [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2</a>, <a href="#S5.4">5.4)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4.	CNS Depressants and Sedating Antihistamines</h2>
<p class="First">When taken with Silenor, the sedative effects of sedating antihistamines and CNS depressants may be potentiated [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2</a>, <a href="#S5.4">5.4)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5.	Tolazamide</h2>
<p class="First">A case of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> has been reported in a type II diabetic patient maintained on tolazamide (1 g/day) 11 days after the addition of oral doxepin (75 mg/day).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8.	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1.	Pregnancy </h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies of Silenor in pregnant women. Silenor should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Administration of doxepin to pregnant animals resulted in adverse effects on offspring development at doses greater than the maximum recommended human dose (MRHD) of 6 mg/day.</p>
<p>When doxepin (30, 100 and 150 mg/kg/day) was administered orally to pregnant rats during the period of organogenesis, developmental toxicity (increased incidences of fetal structural abnormalities and decreased fetal body weights) was noted at ≥100 mg/kg/day. The plasma exposures (AUC) at the no-effect dose for embryo-fetal developmental toxicity in rats (30 mg/kg/day) are approximately 6 and 3 times the plasma AUCs for doxepin and nordoxepin (the primary metabolite in humans), respectively, at the MRHD. When administered orally to pregnant rabbits (10, 30 and 60 mg/kg/day) during the period of organogenesis, fetal body weights were reduced at the highest dose in the absence of maternal toxicity. The plasma exposures (AUC) at the no-effect dose for developmental effects (30 mg/kg/day) are approximately 6 and 18 times the plasma AUCs for doxepin and nordoxepin, respectively, at the MRHD. Oral administration of doxepin (10, 30 and 100 mg/kg/day) to rats throughout the pregnancy and lactation periods resulted in decreased pup survival and transient growth delay at the highest dose. The plasma exposures (AUC) at the no-effect dose for adverse effects on pre- and postnatal development in rats (30 mg/kg/day) are approximately 3 and 2 times the plasma AUCs for doxepin and nordoxepin, respectively, at the MRHD.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2.	Labor and Delivery</h2>
<p class="First">The effects of Silenor on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3.	Nursing Mothers</h2>
<p class="First">Doxepin is excreted in human milk after oral administration. There has been a report of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> occurring in a nursing infant whose mother was taking the higher dose of doxepin used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Caution should be exercised when Silenor is administered to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4.	Pediatric Use</h2>
<p class="First">The safety and effectiveness of Silenor in pediatric patients have not been evaluated<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5.	Geriatric Use</h2>
<p class="First">A total of 362 subjects who were ≥ 65 years and 86 subjects who were ≥ 75 years received Silenor in controlled clinical studies. No overall differences in safety or effectiveness were observed between these subjects and younger adult subjects. Greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Sleep-promoting drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly. A starting dose of 3 mg is recommended in this population and evaluation prior to considering dose escalation is recommended <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6.	Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may display higher doxepin concentrations than healthy individuals. Initiate Silenor treatment with 3 mg in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and monitor closely for adverse daytime effects. <span class="Italics">[see <a href="#S12.5">Clinical Pharmacology (12.5)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7.	Use in Patients with <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">Sleep Apnea</span></h2>
<p class="First">Silenor has not been studied in patients with obstructive <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>. Since hypnotics have the capacity to depress respiratory drive, precautions should be taken if Silenor is prescribed to patients with compromised respiratory function. In patients with severe <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>, Silenor is ordinarily not recommended for use.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="S9"></a><a name="section-9"></a><p></p>
<h1>9.	DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="S9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1.	Controlled Substance</h2>
<p class="First">Doxepin is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="S9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2.	Abuse</h2>
<p class="First">Doxepin is not associated with abuse potential in animals or in humans. Physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of doxepin (e.g., incrementation of dose, drug-seeking behavior).</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="S9.3"></a><a name="section-9.3"></a><p></p>
<h2>9.3.	<span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">In a brief assessment of adverse events observed during discontinuation of doxepin following chronic administration, no symptoms indicative of a withdrawal syndrome were observed. Thus, doxepin does not appear to produce physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-10"></a><p></p>
<h1>10.	OVERDOSAGE</h1>
<p class="First">Doxepin is routinely administered for indications other than <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> at doses 10- to 50-fold higher than the highest recommended dose of Silenor.</p>
<p>The signs and symptoms associated with doxepin use at doses several-fold higher than the maximum recommended dose (Excessive dose) of Silenor for the treatment of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> are described <span class="Italics">[see <a href="#S10.1">Overdosage (10.1)</a>]</span>, as are signs and symptoms associated with higher multiples of the maximum recommended dose (Critical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>) <span class="Italics">[see <a href="#S10.2">Overdosage (10.2)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.1"></a><a name="section-10.1"></a><p></p>
<h2>10.1.	Signs and Symptoms of Excessive Doses</h2>
<p class="First">The following adverse effects have been associated with use of doxepin at doses higher than 6 mg.</p>
<p><span class="Italics">Anticholinergic Effects:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.</p>
<p><span class="Italics">Cardiovascular:</span>  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>.</p>
<p><span class="Italics">Endocrine:</span> raised libido, <span class="product-label-link" type="condition" conceptid="4339088" conceptname="Testicular mass">testicular swelling</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> in males, enlargement of breasts and <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> in the female, raising or lowering of blood sugar levels, and syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span>.</p>
<p><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, and <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> (in association with chlorpromazine).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.2"></a><a name="section-10.2"></a><p></p>
<h2>10.2.	Signs and Symptoms of Critical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">Manifestations of doxepin critical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include:  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> including <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Electrocardiogram changes, particularly in QRS axis or width, are clinically significant indicators of tricyclic compound toxicity. Other signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include, but are not limited to: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, disturbed concentration, transient <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.3"></a><a name="section-10.3"></a><p></p>
<h2>10.3.	Recommended Management</h2>
<p class="First">As management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. In addition, the possibility of a multiple drug ingestion should be considered.</p>
<p>If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is suspected, an ECG should be obtained and cardiac monitoring should be initiated immediately. The patient's airway should be protected, an intravenous line should be established, and gastric decontamination should be initiated. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span> and/or conduction blocks, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is strongly advised. If signs of toxicity occur at any time during this period, extended monitoring is recommended. There are case reports of patients succumbing to fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> late after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>; these patients had clinical evidence of significant <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> prior to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and most received inadequate gastrointestinal decontamination. Monitoring of plasma drug levels should not guide management of the patient.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<p class="First"><span class="Italics">Gastrointestinal Decontamination</span></p>
<p>All patients suspected of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by administration of activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.2"></a><p></p>
<p class="First"><span class="Italics">Cardiovascular</span></p>
<p>A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Serum alkalinization, using intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be used to maintain the serum pH in the range of 7.45 to 7.55 for patients with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> and/or QRS widening. If the pH response is inadequate, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> may also be used. Concomitant use of <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be done with extreme caution, with frequent pH monitoring. A pH &gt;7.60 or a pCO<span class="Sub">2</span> &lt;20 mm Hg is undesirable. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Dysrhythmias</span> unresponsive to sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> therapy/<span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> may respond to lidocaine or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).</p>
<p>In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions, and forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> generally have been reported as ineffective in treatment of tricyclic compound <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.3"></a><p></p>
<p class="First"><span class="Italics">Central Nervous System</span></p>
<p>In patients with central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, early intubation is advised because of the potential for abrupt deterioration. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> should be controlled with benzodiazepines, or, if these are ineffective, other anticonvulsants (e.g., phenobarbital or phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in consultation with a poison control center.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4"></a><p></p>
<p class="First"><span class="Italics">Psychiatric Follow-up</span></p>
<p>Since <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> often is deliberate, patients may attempt <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> by other means during the recovery phase. Psychiatric referral may be appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.5"></a><p></p>
<p class="First"><span class="Italics">Pediatric Management</span></p>
<p>The principles of management of child and adult <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-11"></a><p></p>
<h1>11.	DESCRIPTION</h1>
<p class="First">Silenor (doxepin) is available in 3 mg and 6 mg strength tablets for oral administration. Each tablet contains 3.39 mg or 6.78 mg doxepin hydrochloride, equivalent to 3 mg and 6mg of doxepin, respectively.</p>
<p>Chemically, doxepin hydrochloride is an (E) and (Z) geometric, isomeric mixture of 1 propanamine, 3-dibenz[<span class="Italics">b,e</span>]oxepin-11(6<span class="Italics">H</span>)ylidene-<span class="Italics">N,N</span>-dimethyl-hydrochloride. It has the following structure:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bec1223-5239-4eb6-a9e8-62444106d2c0&amp;name=silenor-01.jpg"></div>
<p>Doxepin hydrochloride is a white crystalline powder, with a slight amine-like odor, that is readily soluble in water. It has a molecular weight of 315.84 and molecular formula of C<span class="Sub">19</span> H<span class="Sub">21</span> NO•HCl.</p>
<p>Each Silenor tablet includes the following inactive ingredients: microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The 3 mg tablet also contains FD&amp;C Blue No.1. The 6 mg tablet also contains D&amp;C Yellow No. 10 and FD&amp;C Blue No. 1.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12.	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1.	Mechanism of Action</h2>
<p class="First">Doxepin binds with high affinity to the histamine H<span class="Sub">1</span> receptor (Ki &lt; 1 nM) where it functions as an antagonist. The exact mechanism by which doxepin exerts its sleep maintenance effect is unknown but is believed due to its antagonism of the H<span class="Sub">1</span> receptor.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-12.2"></a><p></p>
<h2>12.2.	Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Italics">Cardiac Safety</span></p>
<p>In a thorough QTc prolongation clinical study in healthy subjects, doxepin had no effect on QT intervals or other electrocardiographic parameters after multiple daily doses up to 50 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-12.3"></a><p></p>
<h2>12.3.	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>The median time to peak concentrations (Tmax) of doxepin occurred at 3.5 hours postdose after oral administration of a 6 mg dose to fasted healthy subjects. Peak plasma concentrations (Cmax) of Silenor increased in approximately a dose-proportional manner for 3 mg and 6 mg doses. The AUC was increased by 41% and C<span class="Sub">max </span> by 15% when 6 mg Silenor was administered with a high fat meal. Additionally, compared to the fasted state, T<span class="Sub">max</span> was delayed by approximately 3 hours. Therefore, for faster onset and to minimize the potential for next day effects, it is recommended that Silenor not be taken within 3 hours of a meal <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Silenor is widely distributed throughout the body tissues. The mean apparent volume of distribution following a single 6 mg oral dose of Silenor to healthy subjects was 11,930 liters. Silenor is approximately 80% bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Following oral administration, Silenor is extensively metabolized by oxidation and demethylation. The primary metabolite is N-desmethyldoxepin (nordoxepin).</p>
<p>The primary metabolite undergoes further biotransformation to glucuronide conjugates.</p>
<p>In vitro studies have shown that CYP2C19 and CYP2D6 are the major enzymes involved in doxepin metabolism, and that CYP1A2 and CYP2C9 are involved to a lesser extent.</p>
<p>Doxepin appears not to have inhibitory effects on human CYP enzymes at therapeutic concentrations. The potential of doxepin to induce metabolizing enzymes is not known. Doxepin is not a Pgp substrate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.4"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>Doxepin is excreted in the urine mainly in the form of glucuronide conjugates.</p>
<p>Less than 3% of a doxepin dose is excreted in the urine as parent compound or nordoxepin. The apparent terminal half-life (t ½) of doxepin was 15.3 hours and for nordoxepin was 31 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.4"></a><a name="section-12.4"></a><p></p>
<h2>12.4.	 Drug Interactions</h2>
<p class="First">Since doxepin is metabolized by CYP2C19 and CYP2D6, inhibitors of these CYP isozymes may increase the exposure of doxepin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4.1"></a><p></p>
<p class="First"><span class="Bold">Cimetidine:</span></p>
<p>The effect of cimetidine, a non-specific inhibitor of CYP1A2, 2C19, 2D6, and 3A4, on Silenor plasma concentrations was evaluated in healthy subjects. When cimetidine 300 mg BID was co-administered with a single dose of Silenor 6 mg, there was approximately a 2-fold increase in Silenor Cmax and AUC compared to Silenor given alone. A maximum dose of doxepin in adults and elderly should be 3 mg, when doxepin is co-administered with cimetidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.4.2"></a><p></p>
<p class="First"><span class="Bold">Sertraline:</span></p>
<p>The effect of sertraline HCl, a selective serotonin reuptake inhibitor, on doxepin plasma concentrations was evaluated in a daytime study conducted with 24 healthy subjects. Following co-administration of doxepin 6 mg with sertraline 50 mg (at steady-state), the doxepin mean AUC and Cmax estimates were approximately 21% and 32% higher, respectively, than those obtained following administration of doxepin alone. Psychomotor function as measured by the digit symbol substitution test and symbol copy test performance was decreased more at 2-4 hours post dosing for the combination of sertraline and doxepin as compared to doxepin alone, but subjective measures of alertness were comparable for the two treatments.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.5"></a><a name="section-12.5"></a><p></p>
<h2>12.5.	 Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.5.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The effects of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on doxepin pharmacokinetics have not been studied. Because only small amounts of doxepin and nordoxepin are eliminated in the urine, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> would not be expected to result in significantly altered doxepin concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.5.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The effects of Silenor in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied. Because doxepin is extensively metabolized by hepatic enzymes, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may display higher doxepin concentrations than healthy individuals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.5.3"></a><p></p>
<p class="First"><span class="Italics">Poor Metabolizers of CYPs</span></p>
<p>Poor metabolizers of CYP2C19 and CYP2D6 may have higher doxepin plasma levels than normal subjects.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-13"></a><p></p>
<h1>13.	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1.	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>No evidence of carcinogenic potential was observed when doxepin was administered orally to hemizygous Tg.rasH2 mice for 26 weeks at doses of 25, 50, 75 and 100 mg/kg/day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis</span></p>
<p>Doxepin was negative in <span class="Italics">in vitro</span> (bacterial reverse mutation, chromosomal aberration in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and <span class="Italics">in vivo</span> (rat micronucleus) assays.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility</span></p>
<p>When doxepin (10, 30 and 100 mg/kg/day) was orally administered to male and female rats prior to, during and after mating, adverse effects on fertility (increased copulatory interval and decreased corpora lutea, implantation, viable embryos and litter size) and sperm parameters (increased percentages of abnormal sperm and decreased sperm motility) were observed. The plasma exposures (AUC) for doxepin and nordoxepin at the no-effect dose for adverse effects on reproductive performance and fertility in rats (10 mg/kg/day) are less than those in humans at the maximum recommended human dose of 6 mg/day.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-14"></a><p></p>
<h1>14.	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1.	Controlled Clinical Trials</h2>
<p class="First">The efficacy of Silenor for  improving sleep maintenance was supported by six randomized, double-blind studies up to 3 months in duration that included 1,423 subjects, 18 to 93 years of age, with chronic (N=858) or transient (N=565) <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. Silenor was evaluated at doses of 1 mg, 3 mg, and 6 mg relative to placebo in inpatient (sleep laboratory) and outpatient settings.</p>
<p>The primary efficacy measures for assessment of sleep maintenance were the objective and subjective time spent awake after sleep onset (respectively, objective Wake After Sleep Onset [WASO] and subjective WASO).</p>
<p>Subjects in studies of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> were required to have at least a 3-month history of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Chronic Insomnia</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Adults</span></p>
<p>A randomized, double-blind, parallel-group study was conducted in adults (N = 221) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span>. Silenor 3 mg and 6 mg was compared to placebo out to 30 days.</p>
<p>Silenor 3 mg and 6 mg were superior to placebo on objective WASO. Silenor 3 mg was superior to placebo on subjective WASO at night 1 only. Silenor 6 mg was superior to placebo on subjective WASO at night 1, and nominally superior at some later time points out to Day 30.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Elderly</span></p>
<p>Elderly subjects with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> were assessed in two parallel-group studies.</p>
<p>The first randomized, double-blind study assessed Silenor 1 mg and 3 mg relative to placebo for 3 months in inpatient and outpatient settings in elderly subjects (N=240) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span>. Silenor 3 mg was superior to placebo on objective WASO.</p>
<p>The second randomized, double-blind study assessed Silenor 6 mg relative to placebo for 4 weeks in an outpatient setting in elderly subjects (N=254) with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span>. On subjective WASO, Silenor 6 mg was superior to placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Transient Insomnia</span></span></p>
<p>Healthy adult subjects (N=565) experiencing <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">transient insomnia</span> during the first night in a sleep laboratory were evaluated in a randomized, double-blind, parallel-group, single-dose study of Silenor 6 mg relative to placebo. Silenor 6 mg was superior to placebo on objective WASO and subjective WASO.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.3"></a><p></p>
<p class="First"><span class="Italics">Withdrawal Effects</span></p>
<p>Potential withdrawal effects were assessed in a 35-day double blind study of adults with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span> who were randomized to placebo, Silenor 3 mg, or Silenor 6 mg. There was no indication of a withdrawal syndrome after discontinuation of Silenor treatment (3 mg or 6 mg), as measured by the Tyrer's Symptom Checklist. Discontinuation-period emergent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurred in 5% of subjects treated with 6 mg Silenor, versus 0% in 3 mg and placebo subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.4"></a><p></p>
<p class="First"><span class="Italics">Rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> Effects </span></p>
<p>Rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, defined as a worsening in WASO compared with baseline following discontinuation of treatment, was assessed in a double-blind, 35-day study in adults with <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">chronic insomnia</span>. Silenor 3 mg and 6 mg showed no evidence of rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16.	HOW SUPPLIED/STORAGE AND HANDLING </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-15.1"></a><p></p>
<h2>16.1.	How Supplied</h2>
<p class="First">Silenor 3 mg tablets are oval shaped, blue, identified with debossed markings of "3" on one side and "SP" on the other, and are supplied as:</p>
<table width="60%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">NDC 42847-103-30</td>
<td align="left">Bottle of 30</td>
</tr>
<tr>
<td align="left">NDC 42847-103-10</td>
<td align="left">Bottle of 100</td>
</tr>
<tr>
<td align="left">NDC 42847-103-50</td>
<td align="left">Bottle of 500</td>
</tr>
<tr class="Botrule Last">
<td align="left">NDC 42847-103-03</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> trade pack of 30</td>
</tr>
</tbody>
</table>
<p>Silenor 6 mg tablets are oval shaped, green, identified with debossed markings of "6" on one side and "SP" on the other, and are supplied as:</p>
<table width="60%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">NDC 42847-106-30</td>
<td align="left">Bottle of 30</td>
</tr>
<tr>
<td align="left">NDC 42847-106-10</td>
<td align="left">Bottle of 100</td>
</tr>
<tr>
<td align="left">NDC 42847-106-50</td>
<td align="left">Bottle of 500</td>
</tr>
<tr class="Botrule Last">
<td align="left">NDC 42847-106-03</td>
<td align="left"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> trade pack of 30</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-15.2"></a><p></p>
<h2>16.2.	Storage and Handling</h2>
<p class="First">Store at controlled room temperature 20° - 25°C (68° - 77°F), protected from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17.	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Prescribers or other healthcare professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with hypnotics, should counsel them in appropriate use, and should instruct them to read the accompanying Medication Guide [<span class="Italics">see <a href="#S17.4">Medication Guide (17.4)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1.	Sleep-driving and Other Complex Behaviors </h2>
<p class="First">There have been reports of people getting out of bed after taking a hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since "sleep-driving" can be dangerous. This behavior is more likely to occur when a hypnotic is taken with alcohol or other central nervous system depressants [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2</a>, <a href="#S5.4">5.4)</a> and <a href="#S7.3">Drug Interactions (7.3</a>, <a href="#S7.4">7.4)</a></span>]. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a hypnotic. As with "sleep-driving", patients usually do not remember these events.</p>
<p>In addition, patients should be advised to report all concomitant medications to the prescriber. Patients should be instructed to report events such as "sleep-driving" and other complex behaviors immediately to the prescriber.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-16.2"></a><p></p>
<h2>17.2.	<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> risk and Worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>:</h2>
<p class="First">Patients, their families, and their caregivers should be encouraged to be alert to worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, including suicidal thoughts and actions. Such symptoms should be reported to the patient's prescriber or health professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-16.3"></a><p></p>
<h2>17.3.	Administration Instructions </h2>
<p class="First">Patients should be counseled to take Silenor within 30 minutes of bedtime and should confine their activities to those necessary to prepare for bed. Silenor tablets should not be taken with or immediately after a meal [<span class="Italics">see <a href="#S2.3">Dosage and Administration (2.3)</a></span>]. Advise patients NOT to take Silenor when drinking alcohol [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2</a>, <a href="#S5.4">5.4)</a> and <a href="#S7.3">Drug Interactions (7.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-16.4"></a><p></p>
<h2>17.4.	Medication Guide </h2>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>SILENOR<span class="Sup">®</span> (SI-leh-nor) Tablets<br>(<span class="Italics">doxepin</span>) </span></p>
<p>Read this Medication Guide before you start taking SILENOR and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.</p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="First Last"><td align="center"></td></tr></tbody>
</table>
<p><a name="Important"></a><span class="Bold">What is the most important information I should know about SILENOR?</span></p>
<p><span class="Bold">After taking SILENOR, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. </span>You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> with SILENOR. Reported activities include:</p>
<ul class="Disc">
<li>driving a car ("sleep-driving")</li>
<li>making and eating food</li>
<li>talking on the phone</li>
<li>having sex</li>
<li>sleep-walking</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you find out that you have done any of the above activities after taking SILENOR.</span></p>
<p><span class="Bold">Important:</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Take SILENOR exactly as prescribed</span><ul>
<li>Do not take more SILENOR than prescribed.</li>
<li>Take SILENOR 30 minutes before bedtime. After taking SILENOR, you should only do activities needed to get ready for bed.</li>
</ul>
</dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Do not take SILENOR:</span><ul>
<li>with alcohol</li>
<li>if you take other medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>. Talk to your healthcare provider about all of your medicines. Your healthcare provider will tell you if you can take SILENOR with your other medicines</li>
<li>if you cannot get a full night of sleep before you must be active again</li>
</ul>
</dd>
</dl>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="First Last"><td align="center"></td></tr></tbody>
</table>
<p><span class="Bold">What is SILENOR?</span></p>
<p>SILENOR is a hypnotic (sleep) medicine that is used to treat people who have trouble staying asleep.</p>
<p><a name="NotTake"></a><span class="Bold">Who should not take SILENOR?</span></p>
<p>Do not take SILENOR if you:</p>
<ul class="Disc">
<li>take a monoamine oxidase inhibitor (MAOI) medicine or have taken an MAOI in the last 14 days (2 weeks).  Ask your healthcare provider if you are not sure if your medicine is an MAOI.</li>
<li>have an eye problem called narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> that is not being treated</li>
<li>have trouble urinating</li>
<li>are allergic to any of the ingredients in SILENOR. See the end of this Medication Guide for a complete list of ingredients in SILENOR.</li>
</ul>
<p>Talk to your healthcare provider before taking this medicine if you have any of these conditions.</p>
<p>It is not known if SILENOR is safe and effective in children.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking SILENOR?</span></p>
<p><span class="Bold">Before you take SILENOR, tell your healthcare provider if you: </span></p>
<ul class="Disc">
<li>See <span class="Bold">"<a href="#NotTake">Who should not take Silenor?</a>"</span>
</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mental illness, or suicidal thoughts</li>
<li>have severe <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span></li>
<li>have kidney or liver problems</li>
<li>have a history of drug or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span> or addiction</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. It is not known if SILENOR will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.</li>
<li>are breast-feeding or plan to breast-feed. SILENOR can pass into your milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take SILENOR. You should not breast-feed while taking SILENOR.</li>
</ul>
<p>Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements.</p>
<p>SILENOR and other medicines may affect each other causing side effects. SILENOR may affect the way other medicines work, and other medicines may affects how SILENOR works. Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li>a monoamine oxidase inhibitor (MAOI). See <span class="Bold">"<a href="#NotTake">Who should not take SILENOR?</a>"</span>
</li>
<li>cimetidine (Tagamet) or other medicines that can affect certain liver enzymes</li>
<li>certain <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> medicines (antihistamines) or other medicines that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or affect your breathing</li>
<li>the <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine tolazamide</li>
</ul>
<p>Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above.</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I take SILENOR?</span></p>
<ul class="Disc">
<li>Take SILENOR exactly as your healthcare provider tells you to take it.</li>
<li>Your doctor will tell you how many SILENOR to take and when to take them.</li>
<li>Your doctor may change your dose if needed.</li>
<li>
<span class="Bold">Take SILENOR within 30 minutes of bedtime. </span>After taking SILENOR, you should confine your activities to those necessary to prepare for bed.</li>
<li>Do not take SILENOR within 3 hours of a meal. Silenor may not work as well, or may make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> the next day if taken with or right after a meal.</li>
<li><span class="Bold">Do not take SILENOR unless you are able to get a full night of sleep before you must be active again.</span></li>
<li>
<span class="Bold">Call your doctor if your <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span> get worse or do not get better within 7 to 10 days. </span>This may mean that there is another condition causing your <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problem</span>.</li>
<li>If you take too much SILENOR, call your doctor or get medical help right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking SILENOR?</span></p>
<ul class="Disc">
<li>You should not drink alcohol while taking SILENOR. Alcohol can increase your chances of getting serious side effects with SILENOR.</li>
<li>You should not drive, operate heavy machinery, or do other dangerous activities after SILENOR.</li>
</ul>
<p><span class="Bold">You may still feel drowsy the next day after taking SILENOR. Do not drive or do other dangerous activities after taking SILENOR until you feel fully awake.</span></p>
<p><span class="Bold">What are the possible side effects of SILENOR?</span></p>
<p>SILENOR can cause serious side effects including:</p>
<ul class="Disc"><li>See<span class="Bold"> "<a href="#Important">What is the most important information I should know about SILENOR?</a>"</span>
</li></ul>
<p>The most common side effect of SILENOR is <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of SILENOR. For more information ask your healthcare provider or pharmacist. <span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">How should I store SILENOR?</span></p>
<ul class="Disc">
<li>Store SILENOR between 68° and 77° F (20° to 25°C).</li>
<li>Keep SILENOR in a tightly closed container, and away from light. Safely throw away medicine that is out of date or no longer needed.</li>
<li><span class="Bold">Keep SILENOR and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General Information about SILENOR</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SILENOR for a condition for which it was not prescribed. Do not share SILENOR with other people, even if you think they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about SILENOR. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about SILENOR that is written for healthcare professionals.</p>
<p>For more information, contact Pernix Therapeutics, LLC. at 1-877-SILENOR (745-3667) or visit http://www.silenor.com.</p>
<p><span class="Bold">What are the ingredients in SILENOR?</span></p>
<p><span class="Bold">Active Ingredient: </span>doxepin hydrochloride</p>
<p><span class="Bold">Inactive Ingredients: </span>Microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The 3 mg tablet also contains FD&amp;C  Blue No. 1. The 6 mg tablet also contains FD&amp;C Yellow No. 10 and FD&amp;C Blue No. 1.</p>
<p>Manufactured for:<br>Pernix Therapeutics, LLC<br>Morristown, NJ 07960 USA</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>SIL-0030.03.P1A   09/14</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 3 mg Tablet Bottle Label</span></p>
<p><span class="Bold">3</span><span class="Sup">mg</span></p>
<p>30 tablets<br><span class="Bold">Rx Only</span></p>
<p><span class="Bold">silenor</span><span class="Sub">®</span><br>doxepin tablets</p>
<p><span class="Bold">NDC 42847-103-30</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 3 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bec1223-5239-4eb6-a9e8-62444106d2c0&amp;name=silenor-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 6 mg Tablet Bottle Label</span></p>
<p><span class="Bold">6</span><span class="Sup">mg</span></p>
<p>30 tablets<br><span class="Bold">Rx Only</span></p>
<p><span class="Bold">silenor</span><span class="Sub">®</span><br>doxepin tablets</p>
<p><span class="Bold">NDC 42847-106-30</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 6 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bec1223-5239-4eb6-a9e8-62444106d2c0&amp;name=silenor-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SILENOR 		
					</strong><br><span class="contentTableReg">doxepin hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42847-103</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>doxepin hydrochloride</strong> (doxepin) </td>
<td class="formItem">doxepin</td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Cellulose, Microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3;SP</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42847-103-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:42847-103-10</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:42847-103-50</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:42847-103-03</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022036</td>
<td class="formItem">08/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SILENOR 		
					</strong><br><span class="contentTableReg">doxepin hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42847-106</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>doxepin hydrochloride</strong> (doxepin) </td>
<td class="formItem">doxepin</td>
<td class="formItem">6 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Cellulose, Microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Yellow No. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">6;SP</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42847-106-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:42847-106-10</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:42847-106-50</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:42847-106-03</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022036</td>
<td class="formItem">08/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pernix Therapeutics, LLC
							(145577099)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals, Inc</td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">MANUFACTURE(42847-103, 42847-106)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mylan Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">059295980</td>
<td class="formItem">MANUFACTURE(42847-103, 42847-106), PACK(42847-103, 42847-106)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PCI</td>
<td class="formItem"></td>
<td class="formItem">078525133</td>
<td class="formItem">PACK(42847-103, 42847-106)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Plantex Ltd</td>
<td class="formItem"></td>
<td class="formItem">600023907</td>
<td class="formItem">API MANUFACTURE(42847-103, 42847-106)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>83365e51-677a-4496-9e9b-bfc1e81a71ce</div>
<div>Set id: 1bec1223-5239-4eb6-a9e8-62444106d2c0</div>
<div>Version: 4</div>
<div>Effective Time: 20141027</div>
</div>
</div> <div class="DistributorName">Pernix Therapeutics, LLC</div></p>
</body></html>
